Sanofi Operating Income 2010-2024 | SNY
Sanofi annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Sanofi operating income for the quarter ending September 30, 2024 was $4.204B, a 20.02% increase year-over-year.
- Sanofi operating income for the twelve months ending September 30, 2024 was $8.542B, a 17.11% decline year-over-year.
- Sanofi annual operating income for 2023 was $9.594B, a 10.51% decline from 2022.
- Sanofi annual operating income for 2022 was $10.72B, a 8.88% increase from 2021.
- Sanofi annual operating income for 2021 was $9.846B, a 39.92% decline from 2020.
Sanofi Annual Operating Income
(Millions of US $) |
| 2023 |
$9,594 |
| 2022 |
$10,720 |
| 2021 |
$9,846 |
| 2020 |
$16,389 |
| 2019 |
$7,270 |
| 2018 |
$6,232 |
| 2017 |
$7,070 |
| 2016 |
$7,592 |
| 2015 |
$7,038 |
| 2014 |
$8,534 |
| 2013 |
$8,208 |
| 2012 |
$8,547 |
| 2011 |
$10,445 |
| 2010 |
$10,496 |
| 2009 |
$10,903 |
Sanofi Quarterly Operating Income
(Millions of US $) |
| 2024-09-30 |
$4,204 |
| 2024-06-30 |
$1,429 |
| 2024-03-31 |
$1,533 |
| 2023-12-31 |
$1,376 |
| 2023-09-30 |
$3,502 |
| 2023-06-30 |
$2,039 |
| 2023-03-31 |
$2,676 |
| 2022-12-31 |
$2,087 |
| 2022-09-30 |
$4,309 |
| 2022-06-30 |
$1,634 |
| 2022-03-31 |
$2,691 |
| 2021-09-30 |
$3,580 |
| 2021-06-30 |
|
| 2021-03-31 |
$2,527 |
| 2020-09-30 |
$2,927 |
| 2020-03-31 |
$2,338 |
| 2019-09-30 |
$2,516 |
| 2019-03-31 |
$1,538 |
| 2018-03-31 |
$1,549 |
| 2017-12-31 |
$1,188 |
| 2017-09-30 |
$2,434 |
| 2017-06-30 |
$1,596 |
| 2017-03-31 |
$1,851 |
| 2016-12-31 |
$1,842 |
| 2016-09-30 |
$2,722 |
| 2016-06-30 |
$1,724 |
| 2016-03-31 |
$1,305 |
| 2015-09-30 |
$2,308 |
| 2015-06-30 |
$2,131 |
| 2014-06-30 |
$1,977 |
| 2013-06-30 |
$1,545 |
| 2012-06-30 |
$2,183 |
| 2012-03-31 |
$2,582 |
| 2011-12-31 |
$2,047 |
| 2011-09-30 |
$2,184 |
| 2011-06-30 |
$1,596 |
| 2011-03-31 |
$3,061 |
| 2010-12-31 |
$1,360 |
| 2010-09-30 |
$2,954 |
| 2010-06-30 |
$2,940 |
| 2010-03-31 |
$1,961 |
| 2009-12-31 |
$1,057 |
| 2009-09-30 |
$2,874 |
| 2009-06-30 |
$2,908 |
| 2009-03-31 |
$1,973 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$135.190B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
